Zhiyi Pharmaceutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2013

Location

Guangzhou Guangdong China

Primary Industry

Biotechnology

About

Founded in 2013 and based in Guangzhou, Zhiyi Pharmaceutics, Inc. operates as a provider of a biopharmaceutical company that focuses on the research and development of next-generation probiotics and live biotherapeutics. The company has been approved more than 10 projects, including National 863 Special Project and Guangdong Provincial Major New Drug Creation Special Project. It has built a 10,000-square-meter R&D center and pilot plant, including two GMP standard pilot plants. Its SK08(Bacteroides fragilis) was approved for clinical trials in November 2019, Phase II clinical study for safety and tolerability of SK08 has enrolled in 2021. In March 2024, Zhiyi Pharmaceutics raised approximately CNY 100 million in series C funding. The company has established a technical system for the spectra of microorganisms and pathogenic bacteria, the isolation and target identification of new functional strains as well as the development of new live biotherapeutics and active ingredients. The main product, SK08, is an original biopharmaceutical and an in vivo biopharmaceutical developed using a new strain of Bacteroides Fragilis. The SK10 developed by the company can be used for treatment of chemotherapy-associated diarrhea. Zhiyi Pharmaceutics, Inc. will focus on the clinical development of its new drug pipeline, particularly Phase III for SK08.

Current Investors

Shenzhen Capital Real Estate Fund, Nantong Jinxin Tongda Investment Management, Guangzhou Shangdong Asset Management

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy

Website

www.zypharm.com.cn

Company Stage

Series C

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.